Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Paula Ruiz-Briones"'
Autor:
Elena Ramos-Ruperez, Vicente Escudero-Vilaplana, Paula Ruiz-Briones, Roberto Collado-Borrell, Cristina Villanueva-Bueno, José Luis Revuelta-Herrero, Eva González-Haba, Xandra Garcia-Gonzalez, Sara Ibañez-Garcia, Sara Perez-Ramirez, Eduardo Zatarain-Nicolás, Ana Herranz, María Sanjurjo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThe management of cardiotoxicity concerning the use of oral antineoplastic agents (OAAs) is a challenge for healthcare professionals. Our objective was to create a comprehensive medication management guide with dose adjustment recommendation
Externí odkaz:
https://doaj.org/article/53a5cf4d22e14290a294cade5ade3733
Autor:
Rosa Romero-Jimenez, Vicente Escudero-Vilaplana, Esther Chamorro-de-Vega, Arantza Ais-Larisgoitia, Elena Lobato-Matilla, Beatriz Somoza-Fernández, Paula Ruiz-Briones, Carlos González, Ofelia Baniandrés, Luis Menchén, Carmen Lobo-Rodríguez, Ana Herranz, María Sanjurjo
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundPharmacotherapeutic management of immune-mediated inflammatory diseases (IMID) has become more complex due to the development of new treatments, such as biological therapies. Mobile health, especially apps, can provide IMID patients with gr
Externí odkaz:
https://doaj.org/article/b51b42e375584dd6a4307adabfb26375
Autor:
Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina López-López, Cristina Villanueva-Bueno, José Luis Revuelta-Herrero, Paula Ruiz-Briones, Beatriz Somoza-Fernández, Ana Herranz, María Sanjurjo
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Introduction Spironolactone when combined with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) may theoretically exert androgenic properties, thereby compromising the therapeutic effectiveness of abiraterone. Case report Two pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::714d99ff676edfe3a693298c66a0b677
https://pubmed.ncbi.nlm.nih.gov/35037798
https://pubmed.ncbi.nlm.nih.gov/35037798
Autor:
Rosa Romero-Jimenez, Vicente Escudero-Vilaplana, Esther Chamorro-de-Vega, Arantza Ais-Larisgoitia, Maria Elena Lobato Matilla, Beatriz Somoza-Fernandez, Paula Ruiz-Briones, Carlos Gonzalez, Ofelia Baniandres, Luis Menchén, Carmen Lobo-Rodríguez, Ana Herranz-Alonso, Maria Sanjurjo
BACKGROUND Pharmacotherapeutic management of immune-mediated inflammatory diseases (IMID) has become more complex due to the development of new treatments, such as biological therapies. Mobile health, especially apps, can provide IMID patients with g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8733e414896c6d820c9baafcdf1e8f0
https://doi.org/10.2196/preprints.36306
https://doi.org/10.2196/preprints.36306
Autor:
Paula Ruiz-Briones, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Juan Vicente-Valor, Rosa Alvarez, Cristina Villanueva-Bueno, Álvaro Narrillos-Moraza, Ana Herranz, Maria Sanjurjo
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522211437
Introduction Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). It has demonstrated better results concerning effectiveness tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811c7f432d1bc8efae2d32b7cb450fc8
https://doi.org/10.1177/10781552221143787
https://doi.org/10.1177/10781552221143787
Autor:
FJ García-Moreno, Roberto Collado-Borrell, María Olmedo, Maricela Valerio, Elena Lobato-Matilla, Beatriz Somoza-Fernandez, Ana Herranz, Juan Carlos Lopez-Bernaldo-de-Quirós, Teresa Aldámiz-Echevarría, Silvia Manrique-Rodríguez, Emilio Bouza, Sebastian Garcia-Sanchez, Irene Taladriz-Sender, RM Romero-Jiménez, Marina Machado, Paula Ruiz-Briones, Patricia Muñoz, Cecilia M. Fernández-Llamazares, Rafael Correa-Rocha, Milagros Sancho-Gonzalez, José Luis Revuelta-Herrero, Camino Sarobe-González, Alvaro Gimenez-Manzorro, CG Rodriguez-Gonzalez, Esther Chamorro-de-Vega, María Sanjurjo
Publikováno v:
Expert Review of Clinical Pharmacology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Background: We report the long-term outcomes, changes in laboratory parameters, the incidence of secondary nosocomial infections and treatment cost of a Spanish cohort of patients with severe COVID-19 that received tocilizumab (TCZ). Methods: Retrosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c533ed6110c4c54469cd542550b561ee